NFE2L2 and cancer: As these changes could be partly compensated for by the activation of adenosine monophosphate (AMP)-activated protein kinase-a (AMPKα) signaling and consequent adaptive metabolic pathways to maintain energy homeostasis, NRF2-silenced cancer cells are vulnerable to AMPKα inhibition, which suggests the potential for combined inhibition of NRF2 and AMPKα to overcome adaptive behaviors of cancer cells [30].